Ganglioside - IgM antibody

Blood

Report in 192Hrs

At Home

No Fasting Required

Details

Autoantibodies against gangliosides.

₹4,514₹6,449

30% OFF

Ganglioside - IgM Antibody Test Information Guide

Why is it done?
- Detects IgM antibodies against gangliosides, which are glycolipids found in nerve cell membranes, particularly in peripheral and central nervous system myelin
- Primary indication: Diagnosis and assessment of Guillain-Barré Syndrome (GBS) and its variants, particularly acute inflammatory demyelinating polyneuropathy (AIDP)
- Used to identify specific ganglioside targets (GM1, GD1a, GD1b, GM2, GQ1b) in post-infectious neuropathies
- Helps identify Miller Fisher Syndrome (MFS) with anti-GQ1b IgM antibodies
- Typically ordered within 1-2 weeks of symptom onset for optimal detection; IgM antibodies appear early in acute phase
- Can help differentiate between demyelinating and axonal variants of GBS based on antibody patterns
Normal Range
- Reference value: Negative or <1.0 U/mL (units may vary by laboratory)
- Units of measurement: U/mL (Units per milliliter) or optical density (OD) values depending on assay method
- Interpretation - Negative: Absence of IgM antibodies against gangliosides; indicates no acute immune response to these antigens
- Interpretation - Weakly Positive/Borderline: Values between 1.0-1.5 U/mL may indicate early or equivocal response; clinical correlation recommended
- Interpretation - Positive: Values >1.5 U/mL indicate significant IgM antibody levels against specific ganglioside antigens
- Most laboratories report results as: Negative, Equivocal, or Positive based on established cutoff values
Interpretation
- Positive IgM Anti-GM1: Associated with acute motor axonal neuropathy (AMAN); approximately 50% of AMAN cases; indicates antibody-mediated axonal degeneration
- Positive IgM Anti-GD1a: Found in acute motor and sensory axonal neuropathy (AMSAN); associated with more severe disease; higher mortality risk
- Positive IgM Anti-GD1b: Associated with acute inflammatory demyelinating polyneuropathy (AIDP); less common in GBS; may indicate demyelinating pattern
- Positive IgM Anti-GQ1b: Specific for Miller Fisher Syndrome; present in approximately 90% of MFS cases; also found in some AIDP variants
- Positive IgM Anti-GM2: Less frequently detected; may be found in combination with other ganglioside antibodies; associated with sensory symptoms
- Multiple positive antibodies: Indicates more severe disease, poor prognosis, higher mortality rate, and prolonged recovery time
- Negative result does not exclude GBS diagnosis: Up to 40-50% of GBS patients are seronegative for ganglioside IgM antibodies
- Timing affects detection: IgM antibodies are typically highest within first 2-3 weeks of symptom onset; may decline as IgG antibodies appear
- Clinical context critical: Results should be interpreted with clinical presentation, electrodiagnostic findings (EMG/NCS), CSF analysis, and imaging
- Prior Campylobacter jejuni infection: Strong predictor of anti-GM1 positivity; suggests molecular mimicry mechanism
Associated Organs
- Primary organ systems: Peripheral nervous system (PNS), central nervous system (CNS), and neuromuscular junction
- Guillain-Barré Syndrome (GBS): Acute post-infectious autoimmune neuropathy; progressive ascending paralysis; respiratory muscle involvement; 3-5% mortality rate
- Miller Fisher Syndrome (MFS): Variant of GBS; presents with ophthalmoplegia, ataxia, and areflexia; associated with anti-GQ1b antibodies
- Acute Motor Axonal Neuropathy (AMAN): Pure motor axonal variant; associated with anti-GM1 antibodies; more common in Asian populations
- Acute Motor and Sensory Axonal Neuropathy (AMSAN): Most severe form; involves both motor and sensory fibers; poor prognosis; associated with anti-GD1a antibodies
- Infectious triggers: Campylobacter jejuni, Cytomegalovirus, Epstein-Barr virus, Zika virus, and other respiratory/gastrointestinal infections
- Complications of abnormal results: Respiratory failure requiring mechanical ventilation, autonomic dysfunction, cardiac arrhythmias, persistent weakness
- Post-GBS syndrome: Chronic weakness and fatigue affecting 50% of patients; increased mortality in seropositive patients
Follow-up Tests
- Electrodiagnostic studies: Electromyography (EMG) and Nerve Conduction Studies (NCS) to differentiate demyelinating vs. axonal variants
- Ganglioside IgG antibodies: Ordered in subacute phase; helps identify chronic patterns; appears as IgM declines
- Cerebrospinal fluid (CSF) analysis: Lumbar puncture with cell count, protein, glucose; shows albuminocytologic dissociation in GBS
- Brain/spinal cord MRI: To exclude alternative diagnoses; shows nerve root enhancement in some GBS cases
- Infectious disease serology: Campylobacter jejuni IgM/IgG, EBV, CMV, and other pathogenic organisms
- Repeat ganglioside testing: If initial test negative but clinical suspicion high; retest at 1-2 weeks
- Pulmonary function tests (PFT): Monitor for respiratory muscle weakness; vital capacity measurement
- Cardiac monitoring: ECG and Holter monitoring for autonomic dysfunction assessment
- Monitoring schedule: Acute phase - daily clinical assessment; 1-month intervals during rehabilitation; annual follow-up for chronic sequelae
Fasting Required?
- Fasting required: NO - Fasting is not required for this blood test
- Patient can eat and drink normally before blood draw
- No medication restrictions specific to this test
- Immunosuppressive medications should be documented but do not preclude testing
- Recent intravenous immunoglobulin (IVIG) therapy should be noted; may transiently reduce antibody detection
- Blood sample collection: Standard serum tube or specified collection container per laboratory protocol
- Sample handling: Allow blood to clot; separate serum; refrigerate if processing delayed; send on ice if transport time >30 minutes
- Specimen stability: Most stable at 4°C; frozen samples (-20°C) acceptable for 2-4 weeks
- Optimal collection timing: Within 2 weeks of symptom onset for maximum antibody detection; consider repeat testing if initial results negative

How our test process works!